Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Tob Induc Dis ; 222024.
Article in English | MEDLINE | ID: mdl-38362270

ABSTRACT

INTRODUCTION: The smoker's narrative during smoking quitting provides insight into aspects not fully explored in daily clinical practice. The aim of the study was to analyze the smoker narrative using two types of methodologies: content analysis and grounded theory, before and after smoking cessation intervention, provided to the smoker in a specialized Smoking Cessation Unit accredited by the Spanish Society of Pneumology and Thoracic Surgery. METHODS: A prospective observational study of current smokers included in a tobacco cessation program between 2017 and 2020 was conducted at the Smoking Cessation Unit of Santiago de Compostela Health Area, Spain. Routine clinical variables and patient narrative data were collected. A descriptive analysis of the sample, the content of the textual corpus, and a grounded theory were performed in semi-structured interviews at baseline and at follow-up at 6 months. RESULTS: A total of 116 patients were included (mean age 55.6 ± 10.6 years; 56.9% male; mean nicotine dependence score 5.7 ± 1.6). Quantitative analysis of the narrative shows that the most frequent phrases and words are associated with smoking, nicotine craving, and predisposition for smoking cessation. After the intervention, phrases related to the manifestation of abstinence, response to pharmacological treatment, and self-perception of smoking cessation were predominant. In the qualitative analysis, the most frequent categories in the smoker's textual corpus were dependence, motivation, and emotionality, which decreased after the intervention (11.4%, 21.4%, and 9.9%, respectively) accompanied by increased satisfaction (19.2%) and the manifestation of abstinence (21.5%). CONCLUSIONS: Motivation, nicotine dependence, and sensitivity to emotions are all closely intertwined in the current smoker narrative and can be modified as a consequence of treatment.

2.
Ann Thorac Med ; 18(4): 190-198, 2023.
Article in English | MEDLINE | ID: mdl-38058789

ABSTRACT

BACKGROUND: Although pulmonary rehabilitation (PR) is recommended in patients with chronic obstructive pulmonary disease (COPD), there is a scarcity of data demonstrating the cost-effectiveness and effectiveness of PR in reducing exacerbations. METHODS: A quasi-experimental study in 200 patients with COPD was conducted to determine the number of exacerbations 1 year before and after their participation in a PR program. Quality of life was measured using the COPD assessment test and EuroQol-5D. The costs of the program and exacerbations were assessed the year before and after participation in the PR program. The incremental cost-effectiveness ratio (ICER) was estimated in terms of quality-adjusted life years (QALYs). RESULTS: The number of admissions, length of hospital stay, and admissions to the emergency department decreased after participation in the PR program by 48.2%, 46.6%, and 42.5%, respectively (P < 0.001 for all). Results on quality of life tests improved significantly (P < 0.001 for the two tests). The cost of PR per patient and the cost of pre-PR and post-PR exacerbations were €1867.7 and €7895.2 and €4201.9, respectively. The PR resulted in a cost saving of €1826 (total, €365,200) per patient/year, and the gain in QALYs was+0.107. ICER was -€17,056. The total cost was <€20,000/QALY in 78% of patients. CONCLUSIONS: PR contributes to reducing the number of exacerbations in patients with COPD, thereby slowing clinical deterioration. In addition, it is cost-effective in terms of QALYs.

3.
Rev Esp Salud Publica ; 952021 Nov 02.
Article in Spanish | MEDLINE | ID: mdl-34725318

ABSTRACT

OBJECTIVE: Currently in developed countries there is an increase in the consumption of roll your own tobacco, which is associated with a higher proportion of users of this form of tobacco who wish to make an attempt to quit. The objective of this study was to analyze the effectiveness of tobacco cessation interventions based on the type of tobacco consumed. METHODS: Longitudinal study of a cohort of 641 smokers recruited between 2015 and 2018 in a health area of Galicia included in smoking cessation programs, based on psychological counseling and pharmacological treatment. The characteristics and success of the intervention were evaluated in two groups: roll your own tobacco smokers (RYO) and manufactured tobacco smokers (MT). A logistic regression was performed to determine the probability of success in smoking cessation. The risk measure was the odds ratio (OR) with its 95% confidence interval. RESULTS: RYO users started at a younger age and had a lower sociocultural stratum than MT users. Interventions to quit smoking in RYO users were associated with less abstinence at 4 weeks (52% MT vs 38% LT) (OR: 0.5; 95% CI 0.35-0.99; p=0.045;) and at 3 months (42% TM vs 30% TL) (OR:0.6; 95% CI 0.33-0.98; p=0.04). CONCLUSIONS: Smoking cessation programs are less effective in short-term RYO users. There are no differences in long-term abstinence between the two groups.


OBJETIVO: Actualmente en los países desarrollados existe un aumento del consumo de tabaco de liar lo que se asocia a una mayor proporción de usuarios de esta forma de tabaco que desean realizar un intento de abandono. El objetivo de este estudio fue analizar la efectividad de las intervenciones de cesación tabáquica en función del tipo de tabaco consumido. METODOS: Estudio longitudinal de una cohorte de 641 fumadores reclutados entre 2015 y 2018 en un área sanitaria de Galicia incluidos en programas de deshabituación tabáquica, basados en el asesoramiento psicológico y en el tratamiento farmacológico. Se evaluaron las características y el éxito de la intervención en dos grupos: fumadores de tabaco de liar (TL) y fumadores de tabaco manufacturado (TM). Se realizó una regresión logística para determinar la probabilidad de éxito en la cesación tabáquica. La medida de riesgo fue el odds ratio (OR) con su intervalo de confianza al 95%. RESULTADOS: Los consumidores de TL se iniciaron a una edad más temprana y tenían un estrato sociocultural más bajo que los consumidores de TM. Las intervenciones para abandonar el tabaco en los consumidores de TL se asociaron a una menor abstinencia a las 4 semanas (52%TM vs 38% TL) (OR: 0,5; 95%IC 0,35-0,99; p=0,045;) y a los 3 meses (42%TM vs 30%TL) (OR:0,6; 95%IC 0,33-0,98; p=0,04). CONCLUSIONES: Los programas de cesación tabáquica son menos efectivas en los consumidores de TL a corto plazo. No se observan diferencias en la abstinencia a largo plazo entre ambos grupos.


Subject(s)
Smoking Cessation , Tobacco Products , Humans , Longitudinal Studies , Smokers , Spain
5.
Arch. bronconeumol. (Ed. impr.) ; 45(10): 502-507, oct. 2009. tab, graf
Article in Spanish | IBECS | ID: ibc-75940

ABSTRACT

Introducción y objetivoAnalizar la frecuencia, las características y la supervivencia de los pacientes con cáncer de pulmón (CP) y enfermedad pulmonar obstructiva crónica (EPOC), comparándolas con las de pacientes sin EPOC.Material y métodosSe ha realizado un estudio retrospectivo de pacientes diagnosticados de CP mediante citohistología. Se estimó la supervivencia por el método de Kaplan-Meier. El análisis estadístico se realizó con el programa SPSS 15.0.ResultadosSe diagnosticó de CP a 996 pacientes, el 39,8% con EPOC. La edad media (± desviación estándar) de estos últimos era de 70±9,19 años. En cuanto a los estadios GOLD, el 18,2% se encontraba en estadio I, el 53,6% en estadio II, el 24% en estadio III y el 4,2% en estadio IV. Según la citohistología, el 48,2% de los CP eran escamosos, el 22% adenocarcinomas y el 22,5% microcíticos. La supervivencia fue mayor en el grupo con EPOC.ConclusionesEl CP y la EPOC se asocian en un 39,8% de los casos. La estirpe más frecuente del CP es la escamosa y la supervivencia es mayor en el grupo con EPOC(AU)


Background and objectiveTo analyse frequency, characteristics and patient survival with lung cancer (LC) and COPD, comparing them with patients without COPD.Material and methodsA retrospective study, of patients diagnosed by means of cytohistology. Survival was estimated by the Kaplan-Meier method. The statistical analysis was carried out using SPSS 15.0.ResultsA total of 996 patients were diagnosed, 39.8% COPD. Mean age70±9.19 years. GOLD stages: I 18.2%, II 53.6%, III 24%, IV 4.2%. The histological types: squamous cell carcinoma 48.2%, adenocarcinoma 22%, small cell carcinoma 22.5%. Survival was longer in the COPD group.ConclusionsLC and COPD are combined in 39.8%. Squamous cell type is more frequent and survival was longer in the COPD group(AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Lung Neoplasms/mortality , Lung Neoplasms/diagnosis , Lung Neoplasms/epidemiology , Lung Neoplasms/etiology , Lung Neoplasms/surgery , Lung Neoplasms/therapy , Pulmonary Disease, Chronic Obstructive/epidemiology , Pulmonary Disease, Chronic Obstructive/etiology , Pulmonary Disease, Chronic Obstructive/therapy , Survivorship , Nicotiana , Nicotiana/adverse effects , Smoking , Retrospective Studies , Observational Studies as Topic , Cohort Studies
6.
Arch Bronconeumol ; 45(10): 502-7, 2009 Oct.
Article in Spanish | MEDLINE | ID: mdl-19748721

ABSTRACT

BACKGROUND AND OBJECTIVE: To analyse frequency, characteristics and patient survival with lung cancer (LC) and COPD, comparing them with patients without COPD. MATERIAL AND METHODS: A retrospective study, of patients diagnosed by means of cytohistology. Survival was estimated by the Kaplan-Meier method. The statistical analysis was carried out using SPSS 15.0. RESULTS: A total of 996 patients were diagnosed, 39.8% COPD. Mean age 70+/-9.19 years. GOLD stages: I 18.2%, II 53.6%, III 24%, IV 4.2%. The histological types: squamous cell carcinoma 48.2%, adenocarcinoma 22%, small cell carcinoma 22.5%. Survival was longer in the COPD group. CONCLUSIONS: LC and COPD are combined in 39.8%. Squamous cell type is more frequent and survival was longer in the COPD group.


Subject(s)
Adenocarcinoma/epidemiology , Carcinoma, Squamous Cell/epidemiology , Lung Neoplasms/epidemiology , Pulmonary Disease, Chronic Obstructive/epidemiology , Small Cell Lung Carcinoma/epidemiology , Adenocarcinoma/therapy , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/therapy , Cardiovascular Diseases/epidemiology , Combined Modality Therapy , Comorbidity , Diabetes Mellitus/epidemiology , Female , Humans , Kaplan-Meier Estimate , Lung Neoplasms/therapy , Male , Middle Aged , Neoplasms, Second Primary/epidemiology , Palliative Care , Proportional Hazards Models , Retrospective Studies , Small Cell Lung Carcinoma/therapy , Smoking/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...